23858-10-8

Upstream product

• 107-15-3 ethylenediamine 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 7681-11-0 potassium iodide 
• 21500-56-1 tetrachloro(ethylenediamine)platinum(IV) 
• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 14096-51-6 dichloro(ethylenediamine)platinum(II) 
• 616-91-1 N-acetylcystein 
• 37667-27-9 trans,cis-[Pt(en)(OH)2I₂] 
• 23858-09-5 PtBr2(ethane-1,2-diamine) 

Downstream Products

• 52241-27-7 (1,2-diaminoethane)(diaqua)platinum(II) dinitrate 
• 14096-51-6 dichloro(ethylenediamine)platinum(II) 
• 92181-58-3 {N,N'-bis(2,3,5,6-tetrafluorophenyl)ethane-1,2-diaminato^(2-)}dipyridineplatinum(II) 
• 910217-23-1 ethylethylenediamine(benzylmalonato)platinum(II) 
• 41666-77-7 (ethane-1,2-diamine)(malonato)platinum(II) 
• 41626-69-1 [Pt(oxalate)(ethane-1,2-diamine)] 
• 50475-23-5 cis-[Pt(OH₂)₂(ethane-1,2-diamine)]²⁺ 
• 23858-09-5 PtBr2(ethane-1,2-diamine) 

Relevant academic research and scientific papers

Synthesis and characterization of ethylenediamine platinum(II) complexes containing thiourea derivatives. X-ray crystal structures of [Pt(en)(2-imidazolidinethione)2](NO3)2 and [Pt(en)(1-phenyl-2-thiourea)2](NO3)2

Reactions of ethylenediamineplatinum(II) nitrate with thiourea derivatives afford new complexes of the form [Pt(en)L2](NO3)2 [en = ethylenediamine, L = 1-benzyl-2-thiourea (bztu), 1-cyclohexyl-2-thiourea (chtu), 1,3-diethyl-2-thiourea (detu), 1,3-diisopropyl-2-thiourea (diptu), 1-ethyl-2-thiourea (etu), 1-heptyl-2-thiourea (htu), 2-imidazolidinethione (imt), 1-isopropyl-2-thiourea (iptu), 1-phenyl-2-thiourea (phtu), 1-(3-pyridyl)-2-thiourea (pytu), and 1-tert-butyl-2-thiourea (tbtu)]. These complexes are soluble in high polarity solvents and have been characterized by elemental analysis, IR spectroscopy and NMR spectroscopy. IR analyses reveal the characteristic vibrations of the functional groups and the nitrate counter ions. NMR studies show that the chemical shifts of proton and carbon signals of the bonded en are about the same, indicating the bonding of thioureas to the platinum(II) center exert limited trans effect on the en ligand. The observation that thioamide proton signals shift downfield and the thiocarbonyl carbon signals shift upfield as compared to the free thioureas suggests a decrease in thiocarbonyl bond order and an increase in thiocarbonyl carbon-amide nitrogen bond order upon coordination to the platinum(II) center. Good quality single crystals of [Pt(en)(2-imidazolidinethione)2](NO3)2 (7) and [Pt(en)(1-phenyl-2-thiourea)2](NO3)2 (9) are grown by slow evaporation of methanol solution at room temperature. Their molecular structures have been identified by the single crystal X-ray diffraction. Complex 7 crystallizes in the orthorhombic space group Pccn whereas 9 crystallizes in the monoclinic space group P2(1)/n. X-ray crystallographic analysis indicates that the geometry about the platinum atom is square-planar and the crystal packings are dominated by intermolecular en N–H?O (NO3) and thioureas N–H?O (NO3) hydrogen bonds. The two imidazole rings in 7 and the two phenyl rings in 9 are oriented above and below the PtN2S2 plane, respectively, to minimize the steric interaction.

Bisursodeoxycholate(ethylenediamine)platinum(ii): A new autofluorescent compound. Cytotoxic activity and cell cycle analysis in ovarian and hematological cell lines

The present paper describes for the first time an intrinsic fluorescent square-planar platinum(ii) complex carrying two ursodeoxycholate ligands ([Pt(UDC)2(en)], where UDC- = ursodeoxycholate), that emits at room temperature once free in solution. Kinetic studies were carried out in aqueous solution and in the presence of different NaCl concentrations: 4 mM (similar to cytoplasmic concentration) and 150 mM (similar to plasmatic concentration). This novel compound was synthesized from a [PtCl 2(en)] complex and shows increased cytotoxic activity against both resting and cycling HeLa cells, with no toxicity for cell lines derived from neoplastic haematopoietic cells. The Royal Society of Chemistry 2008.

Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents

Four novel platinum complexes, [Pt(en)]2ZL (1), [Pt(en)]2IPrBP (2), [Pt(en)]2MIBP (3) and [Pt(en)]2EIBP (4) [en = ethylenediamine; ZL = 1-hydroxy-3-(1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid, commonly known as zoledronic acid; IPrBP = 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diylbisphosphonic acid; MIBP = 1-hydroxy-2-(2-methyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid; EIBP = 1-hydroxy-2-(2-ethyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid], were prepared and evaluated against five human cancer cell lines, including U2OS, A549, HCT116, MDA-MB-231 and HepG2. While exhibiting lower efficacy on the inhibition of cancer cell lines than cisplatin (CDDP), four complexes showed higher cytotoxicity than the corresponding ligands and relatively stronger cytotoxic effect on the hepatoma cell lines HepG2, and the complex 1 showed higher cytotoxicity than others on the whole. These complexes have better selectivity than the corresponding ligands in inhibiting hepatocarcinoma cells rather than normal liver cells, and the selective inhibitory effect of the complex 1 at the high concentration (100 μM) is better than that at the low concentration. Morphology studies exhibited typical characteristics of cell apoptosis and the cell cycle distribution analysis indicated that the complexes can inhibit cancer cells by inducing the cell cycle arrest at the G2/M phase, exhibiting a similar mechanism of action to CDDP. The binding interaction of complex with DNA has been explored by circular dichroism (CD) and UV-Vis absorption spectra, demonstrating these new complexes have moderate binding affinity for DNA. Graphical Abstract: Four platinum complexes based on imidazolyl-containing bisphosphonates with effective antitumor activity and low hepatotoxicity were designed and evaluated.[Figure not available: see fulltext.]

In vitro and in vivoactivity of series of cationic dinuclearPt(II) complexes

The antitumour potential of nine dinuclear platinum(II) complexes of the type [{Pt(L)Cl}2(μ-X)]2+(where L represents two NH3 or different bidentantly coordinated diamine ligand - ethylenediamine, en; (±)-1,2-propylenediamine, 1,2-pn; isobutylenediamine, ibn; trans-(±)-1,2-diaminocyclohexane, dach; 1,3-propylenediamine, 1,3-pd; 2,2-dimethyl-1,3-propylenediamine, 2,2-diMe-1,3-pd; (±)-1,3-pentanediamine,1,3-pnd, and X is a bridging pyrazine (pz) or pyridazine (pydz) ligand) were determined by in vitro and in vivo assays using the CT26 cell line and a murine model of heterotopic colon cancer tumour induced in immunocompetent BALB/c mice. This study concludes that complexes Pt1, Pt2 and Pt7 possess significant in vitro cytotoxic activity against mouse colon carcinoma CT26 cells, while all these complexes show moderate apoptotic effect. Complexes Pt1 and Pt7 arrested CT26 cells in G2/M phase of cell cycle, while, evaluated by detection of Ki67 expressing cells, complexes Pt5 and Pt6 exerted the highest antiproliferative effect. Complexes Pt1 and Pt2 exerted significant in vivo antitumour effects. These complexes reduced the growth of primary tumour and the incidence of lung and liver metastases without causing the significant hepato- and nephro- toxicity. Our data indicate considerable antitumour activity of platinum(II) complexes against CT26 cells in vitro and in vivo and imply possible further investigations on their role as potential chemotherapeutic agents.

PLATINUM ISOTOPE COMBINED WITH BONE-TARGETING AGENTS FOR USE IN ANTICANCER DRUGS

A compound comprising a bone-seeking agent capable of targeting bone of high metabolic activity (a pyrophosphate or a bisphosphonate) and a radiotoxic element (a Pt isotope, preferably 195mPt or 193mPt, more preferably 195mPt-isotope) is found effective in the synergetic treatment of bone cancer. The use of the compound as a pharmaceutical in the treatment (by targeted short range damage induced by Auger electron emission) and/or diagnosis (by SPECT imaging of gamma emission) of malignant primary and/or metastasised bone cancers.

Structural comparison of ethylenediamine platinum(II) complexes containing thiourea and its di- and tetramethyl substituted derivatives

Three new platinum(II) complexes, [Pt(en)(tu)2](NO3)2 (1), [Pt(en)(dmtu)2] (NO3)2 (2) and [Pt(en)(tmtu)2](NO3)2 (3) (where en = ethylenediamine, tu = thiourea, dmtu = 1,3-dimethyl-2-thiourea and tmtu = 1,1,3,3-tetramethy-2-thiourea), have been synthesized and characterized using elemental analysis, IR spectroscopy and NMR spectroscopy. All complexes are soluble in high polarity solvents. Single crystals have been obtained by slow evaporation of methanol solution at room temperature. NMR studies show that the amide proton signals shift downfield while the thiocarbonyl carbon signals shift upfield as compared to free thioureas. These opposite chemical shifts suggest that there is a decrease in thiocarbonyl bond order and an increase in thiocarbonyl carbon-amide nitrogen bond order for the thioureas upon coordination to platinum(II). The molecular structures of the crystallized complexes have been identified by single crystal X-ray diffraction. Both 1 and 2 crystallize in the monoclinic space groups P2(1)/c and P2(1)/n, respectively, while 3 crystallizes in the orthorhombic space group C222(1). X-ray crystallographic analysis indicates that the geometry about the platinum atom is square-planar and the crystal packings are dominated by intermolecular en N ? H???O (NO3-) and tu N ? H???O (NO3-) hydrogen bonds.

A successful search for new, efficient, and silver-free manufacturing processes for key platinum(ii) intermediates applied in antibody-drug conjugate (ADC) production

A silver-free amination procedure, here called "complexation", was developed to obtain a class of Pt(ii) complexes bearing a payload (such as a diagnostic or a therapeutic moiety). These complexes are crucial intermediates for the efficient development an

METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS

The present invention relates to methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The present invention further relates to the cell targeting conjugates obtainable by said method, to a pharmaceutical composition comprising said conjugates and to the secondary functional moieties as such. The present invention also relates to the use of the cell targeting conjugates in the treatment of cancer.

PLATINUM-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES

The present invention relates to secondary functional moieties comprising a transition metal-based linker and a primary functional moiety bound thereto. The invention also relates to cell targeting conjugates comprising a linker of the invention. The present invention further relates to a medicament comprising said cell targeting conjugate and to the use of the cell targeting conjugates in the diagnosis and treatment of cancer.

Diaminehalogenoplatinum(II) complex reactions with DMSO

The platinum(II) complexes [Pt(N-N)X2] (X = Cl, Br, and I; (N-N) = 1,2-ethanediamine (en) and 1,3-propanediamine (tn)) have been synthesised; their reactions with DMSO in DMSO to substitute halogenide were followed using changing integrals of NMR-spectroscopic signals. The rate constant for [PtenCl2] was found to be 1.0*10?4 s?1 at 300 K and from kinetic runs at different temperatures the energy of activation was estimated as 82 kJ*mol?1 in this case. The rate constant depends on the size of halogenide and was found to be forty times larger for [PtenI2] than for its dichloro-analogue. In the tn-series reactions were a little faster than in the en-series. For all six [Pt(N-N)X2] complexes the solvolysis stopped at the coordination of one DMSO and the six new [Pt(N-N)DMSOX]X were isolated and characterised. Further the [PtenDMSOCl]+ was isolated as its nitrate and perchlorate. DMSO exchange reactions (in DMSO) of [PtenDMSOX]+ were found to be slightly slower than the solvolysis reactions, iodide again giving rise to the most labile system. Ion pair formation in DMSO was found to be modest to almost negligible with a formation constant of 30 M?1 in the case of [PtenDMSOCl]Cl as the largest.